接受抗逆转录病毒治疗的HIV感染者病毒学反弹状态的影响因素及不良后果
Influencing factors and adverse outcomes of virologic rebound states in anti-retroviral-treated individuals with HIV infection.
作者信息
Yuan Defu, Li Mingma, Zhou Ying, Shi Lingen, Lu Jing, Fu Gengfeng, Wang Bei
机构信息
Department of Epidemiology and Health Statistics, Key Laboratory of Environmental Medicine Engineering of Ministry of Education, School of Public Health, Southeast University, Nanjing, China.
Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
出版信息
J Virus Erad. 2023 Mar 4;9(1):100320. doi: 10.1016/j.jve.2023.100320. eCollection 2023 Mar.
Abstract
Antiretroviral therapy (ART) aims to inhibit HIV replication, decrease CD4 T cell loss, and immune function recovery in order to reduce the morbidity and mortality associated with the infection. Treatment should also, improve quality of life and control HIV spread. However, incomplete viral suppression still occurs during ART. Viral suppression and virological failure (VF) thresholds vary between studies in terms of virological rebound (VR) states using different detection thresholds. Further understanding of influencing factors and adverse outcomes in various VR states should provide important guidance for HIV treatment.
摘要
抗逆转录病毒疗法（ART）旨在抑制HIV复制，减少CD4 T细胞损失，并恢复免疫功能，以降低与该感染相关的发病率和死亡率。治疗还应改善生活质量并控制HIV传播。然而，在ART期间仍会出现病毒抑制不完全的情况。在使用不同检测阈值的病毒学反弹（VR）状态方面，不同研究的病毒抑制和病毒学失败（VF）阈值有所不同。进一步了解各种VR状态下的影响因素和不良后果应为HIV治疗提供重要指导。
相似文献
1
Influencing factors and adverse outcomes of virologic rebound states in anti-retroviral-treated individuals with HIV infection.接受抗逆转录病毒治疗的HIV感染者病毒学反弹状态的影响因素及不良后果
J Virus Erad. 2023 Mar 4;9(1):100320. doi: 10.1016/j.jve.2023.100320. eCollection 2023 Mar.
2
Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART?在病毒学得到持续抑制的HIV感染患者中，病毒载量波动和低水平病毒血症发作对抗逆转录病毒治疗有何影响？
J Antimicrob Chemother. 2016 Apr;71(4):1051-5. doi: 10.1093/jac/dkv433. Epub 2015 Dec 24.
3
Molecular biological assessment methods and understanding the course of the HIV infection.分子生物学评估方法与对HIV感染病程的理解
APMIS Suppl. 2003(114):1-37.
4
Very low level viraemia and risk of virological failure in treated HIV-1-infected patients.接受治疗的HIV-1感染患者的极低水平病毒血症与病毒学失败风险
HIV Med. 2017 Mar;18(3):196-203. doi: 10.1111/hiv.12413. Epub 2016 Aug 1.
5
Virologic Failure Following Low-level Viremia and Viral Blips During Antiretroviral Therapy: Results From a European Multicenter Cohort.抗逆转录病毒治疗期间低水平病毒血症和病毒学突破后的病毒学失败：来自欧洲多中心队列的结果。
Clin Infect Dis. 2023 Jan 6;76(1):25-31. doi: 10.1093/cid/ciac762.
6
Cell-Associated HIV-1 Unspliced-to-Multiply-Spliced RNA Ratio at 12 Weeks of ART Predicts Immune Reconstitution on Therapy.治疗 12 周时细胞相关 HIV-1 未剪接至多剪接 RNA 比值预测治疗中的免疫重建。
mBio. 2021 Mar 9;12(2):e00099-21. doi: 10.1128/mBio.00099-21.
7
Factors associated with human immunodeficiency virus-1 low-level viremia and its impact on virological and immunological outcomes: A retrospective cohort study in Beijing, China.与人类免疫缺陷病毒-1 低水平病毒血症相关的因素及其对病毒学和免疫学结果的影响：中国北京的一项回顾性队列研究。
HIV Med. 2022 Mar;23 Suppl 1:72-83. doi: 10.1111/hiv.13251.
8
A Markov model for the effects of virological failure on HIV/AIDS progression in tuberculosis co-infected patients receiving antiretroviral therapy in a rural clinic in northern South Africa.南非北部农村诊所接受抗逆转录病毒疗法的结核合并 HIV 感染者中病毒学失败对 HIV/AIDS 进展影响的马尔可夫模型。
S Afr Med J. 2020 Mar 30;110(4):313-319. doi: 10.7196/SAMJ.2020.v110i4.13934.
9
10
Viro-immunological outcomes after 13-valent pneumococcal vaccination in HIV-1-infected individuals on stable virological suppression.HIV-1 感染者病毒学抑制稳定时 13 价肺炎球菌疫苗接种的病毒免疫结果。
AIDS. 2019 Nov 1;33(13):1987-1994. doi: 10.1097/QAD.0000000000002307.
引用本文的文献
1
Association between baseline HIV-1 DNA levels and clinical outcomes in people living with HIV: a meta-analysis of cohort studies.HIV感染者基线HIV-1 DNA水平与临床结局之间的关联：队列研究的荟萃分析
Emerg Microbes Infect. 2025 Dec;14(1):2508759. doi: 10.1080/22221751.2025.2508759. Epub 2025 May 28.
2
Assessing HIV-1 subtype C infection dynamics, therapeutic responses and reservoir distribution using a humanized mouse model.使用人源化小鼠模型评估HIV-1 C亚型感染动态、治疗反应及病毒库分布。
Front Immunol. 2025 Apr 16;16:1552563. doi: 10.3389/fimmu.2025.1552563. eCollection 2025.
3
Impact of increased uptake of long-acting injectable antiretroviral therapy on HIV incidence and viral suppression in the United States under 2021 FDA guidelines.根据2021年美国食品药品监督管理局（FDA）指南，长效注射用抗逆转录病毒疗法使用增加对美国艾滋病毒发病率和病毒抑制的影响。
AIDS. 2025 Jul 1;39(8):1024-1031. doi: 10.1097/QAD.0000000000004144. Epub 2025 Feb 4.
4
Detectable Virological Load and Associated Factors among People Living with HIV on Antiretroviral Treatment: A Retrospective Study.接受抗逆转录病毒治疗的HIV感染者中可检测到的病毒载量及相关因素：一项回顾性研究
Pathogens. 2024 Apr 27;13(5):359. doi: 10.3390/pathogens13050359.
5
Prevalence and predictors of persistent low-level HIV viraemia: a retrospective cohort study among people receiving dolutegravir-based antiretroviral therapy in Southern Nigeria.持续性低水平HIV病毒血症的患病率及预测因素：尼日利亚南部接受基于多替拉韦的抗逆转录病毒治疗人群的一项回顾性队列研究
Ther Adv Infect Dis. 2024 Apr 2;11:20499361241242240. doi: 10.1177/20499361241242240. eCollection 2024 Jan-Dec.
6
The association of changes in depression severity after the onset of the COVID-19 pandemic and viral nonsuppression among people with HIV.在 COVID-19 大流行发病后抑郁严重程度变化与 HIV 感染者病毒未抑制之间的关联。
AIDS. 2024 May 1;38(6):887-894. doi: 10.1097/QAD.0000000000003828. Epub 2023 Dec 29.
7
8
Predicting Factors of Plasma HIV RNA Undetectability after Switching to Co-Formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Experienced HIV-1 Patients: A Multicenter Study.在有经验的 HIV-1 患者中切换使用比替拉韦、恩曲他滨和丙酚替诺福韦二吡呋酯复方制剂后血浆 HIV RNA 不可检测的预测因素：一项多中心研究。
Viruses. 2023 Aug 12;15(8):1727. doi: 10.3390/v15081727.
本文引用的文献
1
Outcomes of persistent low-level viremia among HIV patients on antiretroviral therapy: A prospective cohort study.接受抗逆转录病毒治疗的HIV患者持续低水平病毒血症的结局：一项前瞻性队列研究。
HIV Med. 2022 Mar;23 Suppl 1:64-71. doi: 10.1111/hiv.13250.
2
Factors associated with human immunodeficiency virus-1 low-level viremia and its impact on virological and immunological outcomes: A retrospective cohort study in Beijing, China.与人类免疫缺陷病毒-1 低水平病毒血症相关的因素及其对病毒学和免疫学结果的影响：中国北京的一项回顾性队列研究。
HIV Med. 2022 Mar;23 Suppl 1:72-83. doi: 10.1111/hiv.13251.
3
Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort.整合酶抑制剂时代低水平HIV病毒血症和病毒学失败的预测因素：一项西班牙全国性队列研究
HIV Med. 2022 Sep;23(8):825-836. doi: 10.1111/hiv.13265. Epub 2022 Mar 1.
4
HIV-1 drug resistance mutations among individuals with low-level viraemia while taking combination ART in Botswana.博茨瓦纳在接受联合抗逆转录病毒治疗（ART）时低病毒血症个体中的 HIV-1 耐药突变。
J Antimicrob Chemother. 2022 Apr 27;77(5):1385-1395. doi: 10.1093/jac/dkac056.
5
Incidence of low-level viremia and its impact on virologic failure among people living with HIV-1 who switched to elvitegravir-based antiretroviral therapy.在转换为基于艾维雷韦的抗逆转录病毒治疗的 HIV-1 感染者中，低水平病毒血症的发生率及其对病毒学失败的影响。
J Glob Antimicrob Resist. 2022 Jun;29:7-16. doi: 10.1016/j.jgar.2022.02.007. Epub 2022 Feb 13.
6
Lower Incidence of HIV-1 Blips Observed During Integrase Inhibitor-Based Combination Antiretroviral Therapy.基于整合酶抑制剂的联合抗逆转录病毒疗法期间观察到HIV-1波动发生率较低。
J Acquir Immune Defic Syndr. 2022 Apr 15;89(5):575-582. doi: 10.1097/QAI.0000000000002898.
7
Virological outcome and frequency of low-level viremia in patients receiving generic dolutegravir-containing regimen at a large tertiary care clinic in Western India.在印度西部一家大型三级护理诊所接受含仿制度鲁特韦治疗方案的患者的病毒学结果及低水平病毒血症发生率
Indian J Sex Transm Dis AIDS. 2021 Jan-Jun;42(1):31-37. doi: 10.4103/ijstd.IJSTD_34_20. Epub 2021 May 3.
8
Persistent Low-Level Viremia is an Independent Risk Factor for Virologic Failure: A Retrospective Cohort Study in China.持续低水平病毒血症是病毒学失败的独立危险因素：一项中国的回顾性队列研究。
Infect Drug Resist. 2021 Nov 2;14:4529-4537. doi: 10.2147/IDR.S332924. eCollection 2021.
9
Low-Level Viremia Is Associated With Cumulative Adherence to Antiretroviral Therapy in Persons With HIV.低水平病毒血症与HIV感染者对抗逆转录病毒疗法的累积依从性相关。
Open Forum Infect Dis. 2021 Sep 17;8(9):ofab463. doi: 10.1093/ofid/ofab463. eCollection 2021 Sep.
10
Prevalence and risk of residual viremia after ART in low- and middle-income countries: A cross-sectional study.中低收入国家抗逆转录病毒治疗后残余病毒血症的流行率和风险：一项横断面研究。
Medicine (Baltimore). 2021 Sep 3;100(35):e26817. doi: 10.1097/MD.0000000000026817.
Zotero 插件